Pfizer Net Profit Margin 1986-2025 | PFE
Current and historical net profit margin for Pfizer (PFE) from 1986 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue. Pfizer net profit margin for the three months ending June 30, 2025 was .
| Pfizer Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2025-06-30 |
$63.83B |
$10.75B |
16.84% |
| 2025-03-31 |
$62.46B |
$7.88B |
12.62% |
| 2024-12-31 |
$63.63B |
$8.03B |
12.62% |
| 2024-09-30 |
$60.43B |
$4.25B |
7.04% |
| 2024-06-30 |
$56.22B |
$-2.60B |
-4.62% |
| 2024-03-31 |
$55.95B |
$-0.31B |
-0.55% |
| 2023-12-31 |
$59.55B |
$2.12B |
3.56% |
| 2023-09-30 |
$70.12B |
$10.48B |
14.95% |
| 2023-06-30 |
$79.27B |
$21.47B |
27.09% |
| 2023-03-31 |
$94.00B |
$29.05B |
30.91% |
| 2022-12-31 |
$101.18B |
$31.37B |
31.01% |
| 2022-09-30 |
$99.88B |
$29.77B |
29.81% |
| 2022-06-30 |
$101.28B |
$29.31B |
28.94% |
| 2022-03-31 |
$92.43B |
$24.97B |
27.01% |
| 2021-12-31 |
$81.29B |
$21.98B |
27.04% |
| 2021-09-30 |
$68.88B |
$19.43B |
28.21% |
| 2021-06-30 |
$55.12B |
$12.76B |
23.14% |
| 2021-03-31 |
$46.08B |
$10.68B |
23.18% |
| 2020-12-31 |
$41.65B |
$9.16B |
21.99% |
| 2020-09-30 |
$32.07B |
$7.73B |
24.10% |
| 2020-06-30 |
$34.47B |
$13.94B |
40.44% |
| 2020-03-31 |
$37.87B |
$15.50B |
40.92% |
| 2019-12-31 |
$40.91B |
$16.03B |
39.18% |
| 2019-09-30 |
$40.22B |
$16.22B |
40.32% |
| 2019-06-30 |
$40.84B |
$12.65B |
30.98% |
| 2019-03-31 |
$41.04B |
$11.48B |
27.97% |
| 2018-12-31 |
$40.83B |
$11.15B |
27.32% |
| 2018-09-30 |
$53.37B |
$23.82B |
44.63% |
| 2018-06-30 |
$53.24B |
$22.55B |
42.35% |
| 2018-03-31 |
$52.67B |
$21.75B |
41.29% |
| 2017-12-31 |
$52.55B |
$21.31B |
40.55% |
| 2017-09-30 |
$52.47B |
$9.81B |
18.69% |
| 2017-06-30 |
$52.35B |
$8.32B |
15.90% |
| 2017-03-31 |
$52.60B |
$7.30B |
13.88% |
| 2016-12-31 |
$52.82B |
$7.22B |
13.66% |
| 2016-09-30 |
$53.24B |
$6.27B |
11.77% |
| 2016-06-30 |
$52.29B |
$7.04B |
13.47% |
| 2016-03-31 |
$50.99B |
$7.62B |
14.95% |
| 2015-12-31 |
$48.85B |
$6.96B |
14.25% |
| 2015-09-30 |
$47.92B |
$8.36B |
17.45% |
| 2015-06-30 |
$48.20B |
$8.90B |
18.46% |
| 2015-03-31 |
$49.12B |
$9.18B |
18.69% |
| 2014-12-31 |
$49.61B |
$9.14B |
18.42% |
| 2014-09-30 |
$50.05B |
$10.48B |
20.93% |
| 2014-06-30 |
$50.33B |
$10.40B |
20.66% |
| 2014-03-31 |
$50.53B |
$21.58B |
42.71% |
| 2013-12-31 |
$51.58B |
$22.00B |
42.65% |
| 2013-09-30 |
$50.88B |
$25.75B |
50.61% |
| 2013-06-30 |
$51.19B |
$26.37B |
51.51% |
| 2013-03-31 |
$52.18B |
$15.53B |
29.75% |
| 2012-12-31 |
$54.66B |
$14.57B |
26.66% |
| 2012-09-30 |
$53.25B |
$9.69B |
18.21% |
| 2012-06-30 |
$56.90B |
$10.22B |
17.97% |
| 2012-03-31 |
$59.42B |
$9.58B |
16.12% |
| 2011-12-31 |
$61.04B |
$10.01B |
16.40% |
| 2011-09-30 |
$65.06B |
$11.46B |
17.62% |
| 2011-06-30 |
$64.44B |
$8.59B |
13.33% |
| 2011-03-31 |
$65.09B |
$8.45B |
12.99% |
| 2010-12-31 |
$65.17B |
$8.26B |
12.67% |
| 2010-09-30 |
$65.50B |
$6.13B |
9.36% |
| 2010-06-30 |
$61.13B |
$8.15B |
13.33% |
| 2010-03-31 |
$54.98B |
$7.93B |
14.43% |
| 2009-12-31 |
$49.27B |
$8.64B |
17.53% |
| 2009-09-30 |
$45.82B |
$8.13B |
17.75% |
| 2009-06-30 |
$46.17B |
$7.53B |
16.32% |
| 2009-03-31 |
$47.32B |
$8.05B |
17.01% |
| 2008-12-31 |
$48.30B |
$8.10B |
16.78% |
| 2008-09-30 |
$48.82B |
$10.56B |
21.63% |
| 2008-06-30 |
$48.84B |
$9.05B |
18.52% |
| 2008-03-31 |
$47.79B |
$7.54B |
15.77% |
| 2007-12-31 |
$48.42B |
$8.14B |
16.82% |
| 2007-09-30 |
$48.15B |
$14.87B |
30.88% |
| 2007-06-30 |
$48.44B |
$17.47B |
36.06% |
| 2007-03-31 |
$49.10B |
$18.62B |
37.92% |
| 2006-12-31 |
$48.37B |
$19.34B |
39.98% |
| 2006-09-30 |
$47.37B |
$12.62B |
26.64% |
| 2006-06-30 |
$46.35B |
$10.85B |
23.40% |
| 2006-03-31 |
$46.06B |
$11.90B |
25.82% |
| 2005-12-31 |
$47.41B |
$8.09B |
17.06% |
| 2005-09-30 |
$47.20B |
$8.18B |
17.33% |
| 2005-06-30 |
$48.77B |
$9.93B |
20.36% |
| 2005-03-31 |
$49.59B |
$9.33B |
18.82% |
| 2004-12-31 |
$48.99B |
$11.36B |
23.19% |
| 2004-09-30 |
$51.57B |
$9.14B |
17.71% |
| 2004-06-30 |
$51.09B |
$8.03B |
15.72% |
| 2004-03-31 |
$48.72B |
$1.58B |
3.24% |
| 2003-12-31 |
$44.74B |
$3.91B |
8.74% |
| 2003-09-30 |
$40.01B |
$6.17B |
15.41% |
| 2003-06-30 |
$35.66B |
$6.28B |
17.61% |
| 2003-03-31 |
$33.05B |
$11.83B |
35.78% |
| 2002-12-31 |
$32.29B |
$9.13B |
28.26% |
| 2002-09-30 |
$29.03B |
$8.23B |
28.34% |
| 2002-06-30 |
$28.86B |
$7.95B |
27.54% |
| 2002-03-31 |
$29.19B |
$7.82B |
26.80% |
| 2001-12-31 |
$29.02B |
$7.79B |
26.83% |
| 2001-09-30 |
$31.14B |
$7.25B |
23.29% |
| 2001-06-30 |
$30.47B |
$6.54B |
21.46% |
| 2001-03-31 |
$29.84B |
$5.86B |
19.64% |
| 2000-12-31 |
$29.41B |
$3.73B |
12.67% |
| 2000-09-30 |
$25.81B |
$3.26B |
12.63% |
| 2000-06-30 |
$21.99B |
$3.30B |
15.00% |
| 2000-03-31 |
$18.78B |
$2.86B |
15.21% |
| 1999-12-31 |
$15.54B |
$3.88B |
24.93% |
| 1999-09-30 |
$14.90B |
$3.63B |
24.37% |
| 1999-06-30 |
$14.90B |
$3.63B |
24.37% |
| 1999-03-31 |
$14.24B |
$3.55B |
24.94% |
| 1998-12-31 |
$13.35B |
$3.43B |
25.69% |
| 1998-09-30 |
$12.39B |
$3.28B |
26.43% |
| 1998-06-30 |
$11.71B |
$2.47B |
21.13% |
| 1998-03-31 |
$11.09B |
$2.30B |
20.77% |
| 1997-12-31 |
$10.74B |
$2.21B |
20.61% |
| 1997-09-30 |
$10.99B |
$2.16B |
19.65% |
| 1997-06-30 |
$11.14B |
$2.08B |
18.64% |
| 1997-03-31 |
$11.31B |
$2.01B |
17.81% |
| 1996-12-31 |
$11.31B |
$1.93B |
17.06% |
| 1996-09-30 |
$10.89B |
$1.84B |
16.86% |
| 1996-06-30 |
$10.63B |
$1.75B |
16.44% |
| 1996-03-31 |
$10.37B |
$1.67B |
16.10% |
| 1995-12-31 |
$10.02B |
$1.57B |
15.69% |
| 1995-09-30 |
$9.58B |
$1.50B |
15.61% |
| 1995-06-30 |
$9.11B |
$1.41B |
15.44% |
| 1995-03-31 |
$8.64B |
$1.35B |
15.61% |
| 1994-12-31 |
$8.28B |
$1.30B |
15.69% |
| 1994-09-30 |
$7.97B |
$1.25B |
15.73% |
| 1994-06-30 |
$7.77B |
$0.70B |
9.05% |
| 1994-03-31 |
$7.59B |
$0.70B |
9.22% |
| 1993-12-31 |
$7.48B |
$0.66B |
8.80% |
| 1993-09-30 |
$7.44B |
$0.65B |
8.71% |
| 1993-06-30 |
$7.39B |
$1.16B |
15.69% |
| 1993-03-31 |
$7.34B |
$1.13B |
15.35% |
| 1992-12-31 |
$7.23B |
$1.08B |
14.88% |
| 1992-09-30 |
$7.13B |
$0.80B |
11.19% |
| 1992-06-30 |
$7.08B |
$0.78B |
10.95% |
| 1992-03-31 |
$7.02B |
$0.73B |
10.46% |
| 1991-12-31 |
$6.95B |
$0.72B |
10.39% |
| 1991-09-30 |
$6.89B |
$0.88B |
12.72% |
| 1991-06-30 |
$6.76B |
$0.84B |
12.49% |
| 1991-03-31 |
$6.62B |
$0.82B |
12.33% |
| 1990-12-31 |
$6.41B |
$0.80B |
12.50% |
| 1990-09-30 |
$6.12B |
$0.73B |
11.99% |
| 1990-06-30 |
$5.91B |
$0.71B |
11.98% |
| 1990-03-31 |
$5.72B |
$0.69B |
12.12% |
| 1989-12-31 |
$5.67B |
$0.68B |
12.02% |
| 1989-09-30 |
$5.55B |
$0.74B |
13.29% |
| 1989-06-30 |
$5.49B |
$0.74B |
13.41% |
| 1989-03-31 |
$5.52B |
$0.81B |
14.72% |
| 1988-12-31 |
$5.39B |
$0.79B |
14.71% |
| 1988-09-30 |
$5.29B |
$0.79B |
14.87% |
| 1988-06-30 |
$5.21B |
$0.76B |
14.52% |
| 1988-03-31 |
$5.10B |
$0.72B |
14.10% |
| 1987-12-31 |
$4.92B |
$0.69B |
14.04% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$201.199B |
$100.330B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
